IV TXA Reduces Peri-Operative Blood Loss & Transfusion Requirement in Periacetabular Osteotomy .
This report has been verified
by one or more authors of the
original publication.
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Intravenous tranexamic acid reduces blood loss and transfusion requirements after periacetabular osteotomy
Bone Joint J. 2020 Sep;102-B(9):1151-1157Eighty-one patients scheduled to undergo elective periacetabular osteotomy (PAO) were randomized to receive IV tranexamic acid (TXA; n=40) or intravenous (IV) normal saline (n=41). The primary outcome of interest was total peri-operative calculated blood loss. The secondary outcomes of interest included the incidence of allogeneic transfusion, length of hospital stay, incidence of complications at 6-weeks follow-up, and peri-operative cell saver usage. The results of this randomized controlled trial demonstrated that the primary outcome was statistically significantly reduced in the TXA group vs saline group (1,264.6 mL [SD 321.4] vs 1,515.4 mL [SD 393.9]; p=0.002). Furthermore, the incidence of allogenic transfusions was statistically significantly lower in the TXA group compared to the saline group (4 vs 15; p=0.008). All other outcomes were not statistically significantly different between the 2 treatment groups (p>0.05). Regression analysis was also conducted adjusting for factors including age, sex, BMI, pre-operative hemoglobin, cell-saver volume, peri-operative mean arterial pressure, and surgical time -- regression results suggested that using IV TXA was a predictor of lower calculated blood loss (p<0.001) and a negative predictor of allogenic transfusion use (p=0.007).
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
